Synthesis and Initial Characterization of a Reversible, Selective $^{18}$F-Labeled Radiotracer for Human Butyrylcholinesterase

Christian Gentzsch,1 Xinyu Chen,2,3,4 Philipp Spatz,1,3 Urban Košak,5 Damijan Knez,5 Naoko Nose,6 Stanislav Gobec,5 Takahiro Higuchi,3,4,6 Michael Decker1

1Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy and Food Chemistry, Julius-Maximilians-University of Würzburg, Am Hubland, 97074, Würzburg, Germany
2Department of Nuclear Medicine, University Hospital of Augsburg, Stenglinstraße 2, 86156, Augsburg, Germany
3Department of Nuclear Medicine, University Hospital of Würzburg, Oberdürbacher Straße 6, 97080, Würzburg, Germany
4Comprehensive Heart Failure Center, University Hospital of Würzburg, Am Schwarzenberg 15, 97078, Würzburg, Germany
5Chair of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, SI-1000, Ljubljana, Slovenia
6Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata-cho, Kita-ku, Okayama, Japan

Abstract

Purpose: A neuropathological hallmark of Alzheimer’s disease (AD) is the presence of amyloid-β (Aβ) plaques in the brain, which are observed in a significant number of cognitively normal, older adults as well. In AD, butyrylcholinesterase (BChE) becomes associated with Aβ aggregates, making it a promising target for imaging probes to support diagnosis of AD. In this study, we present the synthesis, radiochemistry, in vitro and preliminary ex and in vivo investigations of a selective, reversible BChE inhibitor as PET-tracer for evaluation as an AD diagnostic.

Procedures: Radiolabeling of the inhibitor was achieved by fluorination of a respective tosylated precursor using K[$^{18}$F]. IC$_{50}$ values of the fluorinated compound were obtained in a colorimetric assay using recombinant, human (h) BChE. Dissociation constants were determined by measuring hBChE activity in the presence of different concentrations of inhibitor.

Results: Radiofluorination of the tosylate precursor gave the desired radiotracer in an average radiochemical yield of 20 ± 3 %. Identity and > 95.5 % radiochemical purity were confirmed by HPLC and TLC autoradiography. The inhibitory potency determined in Ellman’s assay gave an IC$_{50}$ value of 118.3 ± 19.6 nM. Dissociation constants measured in kinetic experiments revealed lower affinity of the inhibitor for binding to the acylated enzyme ($K_2 = 68.0$ nM) in comparison to the free enzyme ($K_1 = 32.9$ nM).

Conclusions: The reversibly acting, selective radiotracer is synthetically easily accessible and retains promising activity and binding potential on hBChE. Radiosynthesis with $^{18}$F labeling of tosylates was feasible in a reasonable time frame and good radiochemical yield.

Key words: Alzheimer’s disease, Enzyme inhibitor, Positron emission tomography, Biodistribution, Quaternization
Introduction

Alzheimer’s disease (AD) is an incurable, progressive neurodegenerative disorder and the most frequent cause of dementia with high prevalence and a long asymptomatic phase [1, 2]. The number of dementia-diseased individuals is expected to further increase, due to a growing average age and demographic change, which is hard to overcome for health care systems and society as a whole [3]. The definitive diagnosis of AD should no longer be solely based on typical, clinical symptoms, since they are not conclusive enough and begin many years after initial neuropathological alterations [4–6]. At this point, a successful disease-modifying or even preventive therapy is already impossible. Due to this fact, there is an urgent need for biological targets and biomarkers of an early disease state to help not only for an early, conclusive diagnosis with respective imaging probes but also to shed new light in the sequences and significances of the various neuropathological processes involved [7]. Three of the four FDA-approved anti-AD medications temporarily ameliorate AD symptoms by inhibiting cholinesterases (ChEs), whereby donepezil and galantamine are selective acetylcholinesterase (AChE) inhibitors and rivastigmine additionally binds to the isoenzyme butyrylcholinesterase (BChE). AChE inhibition prevents degradation of the neurotransmitter acetylcholine, levels of which are decreasing through cell death of cholinergic neurons [8–10]. However, advanced progression of AD involves a rapid decrease of AChE levels in the brain of ~90%, which is accompanied in later-stage AD by elevated BChE expression. AChE and BChE exhibit very different localisations, biochemical features, and physiological functions [11]; however, BChE can take over the hydrolytic function of AChE [12–16]. These findings make BChE an attractive target for the development of more potent drugs for combatting AD [8–10]. Established pathological AD hallmarks are the abnormal metabolism of amyloid-β (Aβ), accompanied by hyperphosphorylated tau (τ) proteins, oxidative stress, and alterations concerning microglia cells in nervous tissue [17]. Aβ peptide can impair neurovascular homeostasis by its cerebrovascular effects, causing endothelial dysfunction [18]. Interestingly, Aβ deposits develop in nearly 30% of aged adults, who do not show pathologically deteriorated cognition or memory deficits [19]. However, in AD patients, there is an increased expression of BChE along with Aβ plaques, especially in the cerebral cortex [20, 21]. In this outer layer of cerebrum, there is usually no considerable amount of BChE in healthy people, suggesting that the enzyme plays a potential key role in generating the detrimental attributes of Aβ. This finding has been supported in a BChE knockout mouse model, where distinctly fewer fibrillar Aβ plaques have been detected [15]. In this context, it is highly promising to apply suitable radiotracers in positron emission tomography (PET) studies, since this imaging technique exhibits excellent sensitivity and can provide an accurate estimation of the radiotracers’ in vivo concentration and biodistribution [22]. ChE PET tracers have been developed, with the majority of them targeting peripheral or brain AChE [23]. These compounds can be classified in two main categories, substrate-based and ligand-based tracers. The latter can be reversible or irreversible inhibitors. Substrate-based tracers, which usually have a high blood-brain barrier (BBB) permeability, can have intrinsic drawbacks due to quick hydrolysis and delivery limitations into the tissue [24]. In consequence, they may not reflect the regional enzyme distribution, but rather plasma delivery rate of the tracer [25]. Irreversible inhibitor-derived tracers can have a complex mechanism of enzyme inactivation and it is often complicated to accurately determine in vivo kinetics and distribution [24, 26]. Examples of substrate-type tracers specific for BChE include N-methylpiperidin-4-yl 4-[123I]iodobenzoate ([123I]MP4Bz), N-[18F]fluoroethylpiperidin-4-ylmethyl butyrate, and 1-[11C]-methyl-4-piperidinyl n-butyrate ([11C]MP4B) [16, 27, 28]. [11C]MP4B enters the brain, but no enhanced activity can be seen in regions where BChE-associated plaques typically show up in AD, which is likely the same for N-[18F]fluoroethylpiperidin-4-ylmethyl butyrate. In preliminary in vivo studies, the tracer showed high initial uptake in rat cerebral cortex after intravenous injection, but the hydrolysis rate of these ester is presumably still too high [28]. [123I]MP4Bz was applied in single-photon emission computed tomography (SPECT) studies, in which it was possible to distinguish cerebral cortical BChE activity in wild-type mice from an AD model [16]. This represents an important proof of concept, which demonstrates that BChE can indeed serve as a promising biomarker in AD diagnostics [15, 21]. This could also be shown for the pseudoirreversible BChE inhibitor phenyl 4-[123I]iodophenylcarbamate ([123I]-PIP), which accumulated specifically in Aβ plaques with ChE activity in human AD brain tissue [29]. Additionally, this tracer has been investigated very recently as a potential diagnostic and treatment monitoring tool for BChE activity changes in multiple sclerosis showing promising preliminary results [30]. Regarding irreversible and highly selective inhibitors of BChE as radiotracers, carbamate-based inhibitors were investigated that transfer the radiolabeled moiety onto the enzyme, where it is covalently bound. Ex vivo autoradiography on mice brain tissue and kinetic investigations proved such covalent transfer [24]. Furthermore, investigations into the influence of the carbamate structure that is transferred to BChE were made by altering spacer lengths and attached heterocyclic moieties. This resulted in sets of inhibitors with short, medium and long duration of action and pronounced neuroprotectivity in an AD mouse model, showing also the therapeutic potential of such inhibitors [31]. Altogether, these results support BChE not only as a promising biomarker for an early diagnosis of AD but also as an attractive target to be addressed by imaging probes in order to shed the light on the complex neuropathology of AD. Herein, we report on synthesis, in vitro evaluation, radiolabeling, ex vivo autoradiography, and
preliminary in vivo PET studies of an $^{18}$F-labeled BChE selective tracer, based on the structure of a potent, selective BChE inhibitor with reversible binding mode (Fig. 1a, b) [32]. Our intention was to utilize the promising properties of the parent compound for a suitable radiotracer, and these properties include the high affinity and selectivity towards the target enzyme, accompanied by pronounced lipophilicity and a relatively low molecular weight, which is favorable for blood-brain barrier (BBB) penetration [33]. Additionally, we chose a reversible inhibitor to overcome the intrinsic problems of substrate-type and irreversible radiotracers mentioned before, possibly enabling a more precise mapping of BChE distribution. We decided to replace the methoxy group on the ethylene-side chain with fluorine, because this moiety points out of the binding pocket as observed in the resolved crystal structure of the enzyme in complex with the parent inhibitor [32]. We assumed that this modification would retain most of inhibitory potency. We chose to incorporate $^{18}$F as radioisotope to take advantage of a long half-life and high positron yields in combination with a good spatial resolution due to relatively low positron energies in comparison to other radioisotopes commonly used for PET studies (e.g., $^{18}$F: 0.65 MeV, $^{68}$Ga: 1.90 MeV) [34, 35].

**Materials and Methods**

**Chemistry**

The non-radioactive “cold” inhibitor 4 and precursor 5 for radiolabeling were synthesized as shown in Fig. 2. Briefly, the piperidine ring of building block 1 was benzylated under Leuckart-Wallach conditions [36]. Subsequent demethylation of the methoxy group in compound 2 applying BF$_3$ · Et$_2$O in propane-1-thiol [37] gave the central building block,
the alcohol 3, which can also be obtained from commercially available nipeotic acid (Fig. 2) [38]. Cold compound 4 was obtained by fluorination of 3 with diethylaminosulfur trifluoride (DAST) [39]. For radiolabeling with K[18F], a tosylate-leaving group was chosen, which was introduced by reacting 3 with p-toluenesulfonyl chloride (TosCl). We chose this synthetic strategy to utilize the advantage of having one central building block for generating both the precursor 5 for radiolabeling and the cold reference compound 4.

**In Vitro Studies**

The inhibitory potency of compound 4 (Fig. 2) on hBChE was determined in the colorimetric Ellman’s assay [40]. The incubation time of the compound stock solution (100 % in dimethylsulfoxide, DMSO) with Ellman’s reagent (5,5′-dithiobis-(2-nitrobenzoic acid), DTNB) and recombinant hBChE was 5 min. The final concentrations were 370 μM of DTNB and 1 nM of the enzyme in a 0.1-M phosphate buffer at pH = 8.0. Reactions were started by addition of butyrylthiocholine iodide (BTCI) in a concentration of 500 μM with a final DMSO content of 1 %. IC₅₀ values were determined by plotting residual enzyme activities against seven respective inhibitor concentrations. Tacrine served as a positive control (cf. ESM for further experimental details).

Kinetic studies to measure dissociation constants K₁ and K₂ of inhibitor 4 for binding to the free and acylated enzyme were performed by measuring progress curves of product formation with ~ 50 μM BTCI as substrate. BTCI hydrolysis by hBChE was measured in the absence and presence of inhibitor 4 at three different concentrations (namely 40 nM, 80 nM, and 160 nM, respectively). The experiments were carried out at 25 °C in 25-mM phosphate buffer (pH = 7.0) according to the method of Ellman [40]. The concentration of purified hBChE, which was always the final addition to the assay probes, was approx. 1 nM. The hydrolysis of 46 μM BTCI was followed until completion in the presence of 1 mM DTNB (cf. ESM for further experimental details).

**Radiochemistry**

Radiofluorination of tosylate precursor 5 (Fig. 2) was performed in an established procedure. ¹⁸F-Fluoride was separated from ¹⁸O-water by an anion-exchange cartridge, which was eluted with 300 μl of 66-mM K₂CO₃ aqueous solution into a vial containing 15 mg of Kryptofix₂₂₂ in 500-μl acetonitrile. The mixture was dried azeotropically at 120 °C, which was repeated twice using dry acetonitrile (500 μl each time). Then, 1 mg of the precursor 5 (Fig. 2) in 400 μl of dry acetonitrile was added to the mixture and reacted for 10 min at 110 °C. After cooling to room temperature, the reaction mixture was neutralized by adding 5 % acetic acid (300 μl). The labeled compound was purified by semi-preparative, reversed phase HPLC (cf. ESM for further experimental details). Tracer identity and sufficient radiochemical purity were
confirmed by radio-thin layer chromatography (TLC). The radiotracer was diluted with saline to the required concentration for further investigation.

**Preliminary Ex Vivo Tissue Binding Assay and In Vivo PET Imaging**

Animal protocols were approved by the local Animal Care and Use Committee and conducted according to the Guide for the Care and Use of Laboratory Animals. One C57BL/6N mouse from Charles River was used for ex vivo tissue binding studies. Horizontal slices with 20-μm thickness were made and separated into two series for either control or blocking group. The frozen mice brain slices were incubated in a buffer at pH = 8.0 (150-mM NaCl, 5-mM EDTA, 50-mM Na₂HPO₄) containing ¹⁸F-labeled compound in a buffer at pH = 8.0 (150-mM NaCl, 5-mM EDTA, 50-mM Na₂HPO₄) containing ¹⁸F-labeled compound in a buffer at pH = 8.0 (150-mM NaCl, 5-mM EDTA, 50-

**Results**

**Chemistry**

The fluorinated, reversible hBChE inhibitor 4 (Fig. 2) was synthesized in three steps with satisfying yields [36, 37, 39]. We applied the DAST fluorination method for alcohol 3 due to the short reaction times, mild conditions, and uncomplicated workup, despite lower yields (24%). This compound was only required in minor amounts as reference during radiolabeling and for in vitro assays. The respective precursor for ¹⁸F-labeling was synthesized using the same building block, alcohol 3, in almost quantitative yields. However, precursor 5 exhibited an instability problem, when present as free base. It was resolved by turning 5 into its tosylate salt. During purity control by liquid chromatography/mass spectrometry (LCMS), we found a slow side reaction due to intramolecular ring closure by nucleophilic attack of the piperidine nitrogen (Fig. 3). This can be explained with the excellent leaving group quality of tosylate, which is on the one hand required for a facile radiolabeling under preferably mild conditions, but makes the compound sensitive for this quaternization side reaction on the other hand. Since building block 1 is not commercially available, we synthesized alcohol 3 additionally out of low cost and easy to handle nipecotic acid 6 (Fig. 2) [36, 37]. In the first step, the piperidine nitrogen was benzyolated in very good yields applying benzoyl chloride. Next, the carboxylic acid of compound 7 was activated with 3-[bis(dimethylamino)methyl]imidazole-3H-benzotriazol-1-oxide hexafluorophosphate (HBTU) and coupled to 2-aminoethanol in very good yields. Subsequently, compound 8 was protected at its hydroxyl group with tert-butylmethylsilyl chloride (TBDMS-Cl) in good yields. Finally, both amide groups were reduced with lithium aluminum hydride and the crude product was used directly in a one-pot-two-steps manner to be coupled naphthalene-2-sulfonfyl chloride at the reduced secondary amine function. It was found that the TBDMS group is cleaved under the applied conditions and alcohol 3 (Fig. 2) was obtained in satisfying yields.

**In Vitro Studies**

Subsequently, compound 4 was tested in an Ellman’s assay for its inhibitory potency against hBChE [40]. We determined a low submicromolar value (IC₅₀ = 118.3 ± 19.6 nM), meaning a drop in inhibitory potency compared to the parent methoxy derivative (Fig. 1a, b; IC₅₀ = 4.9 ± 0.3 nM) [32]. This can be explained by means of the BChE crystal structure in complex with the inhibitor. Although the methoxy-ethylene moiety as a whole rather points out of the binding pocket, the missing methoxy-oxygen has been described to act as an additional H-bond acceptor with a structural water and Asn68 (Fig. 1b). This is still a good compromise, since the structure-activity relationships revealed that other positions to introduce fluorine in the molecule would presumably lead to a more drastic decline of activity (cf. Table 1). Still, this class of compounds exhibits high selectivity over hAChE, which had been described also for several derivatives thereof [32].

To gain in-depth insight into the binding potential of inhibitor 4, the effects of different concentrations of the compound on hBChE activity were studied by measuring progressive curves of product formation at approximately 50 μM of BTCI (Fig. 4a). The analysis of these progressive curves revealed good agreement between the experimental curves (Fig. 4a, in blue) and a theoretical model (Fig. 4a, in red) that defined a mixed reaction mechanism with binding of the inhibitor to both the free and the acylated enzyme (Fig. 4b). The dissociation constants revealed that the binding affinity of compound 4 to the acylated enzyme (K₂ = 68.0 nM) is lower than to the free enzyme (K₁ = 32.9 nM).

**Radiochemistry**

Next, precursor 5 (Fig. 2) was subjected to ¹⁸F-radiolabeling. We obtained [¹⁸F]-labeled tracer 4 in
approximately 120 min with an average radiochemical yield of 20 ± 3 % (decay-corrected, \( n = 2 \)) without reaction condition optimization. The identity of the tracer and its radiochemical purity (≥ 95.3 %) were confirmed by TLC autoradiography. In a preceding \(^{18}\)F radiolabeling approach of precursor 5 applying established conditions as described before (cf. “Materials and Methods”), we were able to verify tracer identity by its \( R_f \) value on radio-TLC. TLC autoradiography indicated a progress of fluorination by more than 33 % (Fig. 5c). Furthermore, the retention time of the radiotracer (\( \gamma \) detection, Fig. 5b) corresponded to that of the cold compound on HPLC (UV detection, Fig. 5a).

### Preliminary Ex Vivo Tissue Binding and In Vivo PET Imaging

In the ex vivo autoradiography study, we found accumulation of high radioactivity in most of the brain area, especially high intensity at the cortex, where BChE activity is elevated even more during AD progression [41]. Ethopropazine hydrochloride, a selective and reversible inhibitor of BChE [42], successfully reduced tracer uptake, suggesting specific binding of the tracer to BChE in the brain tissue (Fig. 6a). Unfortunately, dynamic PET images in a healthy rat indicated low tracer retention in brain (Fig. 6b, c).

![Fig. 3. Quaternization of precursor 5 when present as free base.](image-url)

| \( R \) | \( R^1 \) | \( R^2 \) | \( IC_{50} \pm SEM^a \) (nM) on \( hBChE \) | \%RA\(^b \) \pm SEM at 10 \( \mu M \) on \( mAChE \) |
|---|---|---|---|---|
| \( \text{Ph} \) | -(CH\(_2\))\(_2\)-F | | 118.3 ± 19.6 | - |
| \( \text{F-Ph} \) | -(CH\(_2\))\(_2\)-OMe | | ~ 53000 | - |
| \( \text{Ph} \) | -(CH\(_2\))\(_3\)-OMe | | 14.4 ± 0.8 | 95% ± 5% |
| \( \text{Ph} \) | -(CH\(_2\))\(_2\)-OMe | | 156 ± 33 | 95% ± 7% |

Table 1 Structures and inhibitory potencies of cold, reversible \( hBChE \) inhibitor 4 (Fig. 2) in contrast to respective derivatives with substituted benzyl group, naphthalene group, and altered alkyl chain length on sulfonamidic nitrogen [32]. \(^a\)SEM standard error of means, \(^b\)RA residual activity
Discussion

In our synthetic approach towards cold, reversible $h$BChE inhibitor $4$, and the respective precursor $5$ for $^{18}$F labeling (Fig. 2), we were able to perform several optimizations of reaction conditions. Yields of the Leuckart-Wallach benzyla-
tion in the first step were significantly increased, when benzaldehyde was freshly distilled before the reaction to remove benzoic acid, which is formed due to slow oxidation of benzaldehyde in the presence of air [36, 43]. In the next step, we achieved demethylation of a methoxy group with boron trifluoride etherate in propane-1-thiol. However, at first, this step required long reaction times (6–7 days), even though it was described that increased amounts of BF$_3$·Et$_2$O can accelerate conversion [37]. We found that slightly elevated temperatures (up to 50 °C) significantly decreased reaction times (60 h). Fluorination of the alcohol $3$ with DAST gave the desired product $4$; however, attempts to increase the yields failed. This is likely due to the side reactions that can appear when DAST is applied, namely elimination or carbonium-ion type rearrangements [39]. Tosylation of alcohol $3$ proceeded almost quantitatively under standard conditions [44]; however, the product has to be turned into its tosylate salt to prevent slow, but continuous quaternization (Fig. 3). In our additional synthetic approach towards central building block $3$ (Fig. 2), we found that both amide groups of TBDMS-protected compound $9$ can be reduced by lithium aluminum hydride and the crude product can directly be coupled to naphthalene-2-sulfonyl chloride to obtain deprotected alcohol $3$. This abbreviates the synthetic procedure by one additional TBDMS-deprotection step.

Next, we measured the inhibitory potency of our cold, reversible $h$BChE inhibitor $4$ in a colorimetric Ellman’s assay and determined an $IC_{50}$ value of 118.3 ± 19.6 nM, meaning a significant drop of inhibitory activity compared to the parent compound (Fig. 1a, $IC_{50} = 4.9 ± 0.3$ nM). However, the structure-activity relationships for this class of compounds revealed that altering the $N$-alkyl moieties of the sulfonamide nitrogen led to the lowest changes in inhibitory
potency, while substituted naphthalene or benzyl groups significantly decreased inhibitory potency (Table 1 and Fig. 1b) [32]. As an example, we synthesized a respective derivative with a fluoromethyl group in para position of the benzyl ring, which turned out to be almost inactive as hBChE inhibitor (Table 1). Even though replacement of the methoxy group with a fluorine atom reduced inhibitory potency more than expected considering the previously established structure-activity relationships, the submicromolar IC₅₀ value in combination with the high selectivity ratio over AChE for this class of compounds still represent promising attributes for a suitable radiotracer [33]. Additionally, kinetic experiments revealed a good binding potential of compound 4 (Fig. 2) to hBChE. The dissociation constant K₁, representing the binding affinity to the free enzyme, was generally lower than K₂, the respective constant for binding to the acylated enzyme (K₁ = 32.9 nM, K₂ = 68.0 nM, cf. Fig. 4).

Subsequently, we performed ¹⁸F-radiolabeling of the tosylate precursor 5 by nucleophilic substitution. Applying an established procedure with some variations on the technical details led to a reasonable radiochemical yield. Importantly, the whole process including labeling, tracer identification, and purification was feasible in approximately 120 min, considering the half-life of ¹⁸F (1.8288 h) as a limiting factor for time-consuming preparations of radiotracers [34]. In a precedent radiolabeling approach, we could already determine a facile progress of fluorination by TLC autoradiography. The tracer identity could be confirmed both by radio-TLC and HPLC retention times (Fig. 5). Since harsh radiolabeling conditions can lead to decomposition of unstable functional groups and unexpected side reactions of the respective precursor, our promising radiolabeling results motivated us to perform preliminary ex vivo and in vivo investigations.

The ex vivo autoradiography study demonstrated good binding of our tracer to BChE rich areas in mice brain tissues. We observed high intensities in cortex, which is in good agreement with the known BChE distribution in mice brain [45–47]. After preincubating the tissue with ethopropazine hydrochloride, a selective inhibitor of BChE [42], we found a significant decrease of binding (Fig. 6a). This finding met our expectations and provides further evidence of the pronounced selectivity over AChE for this compound. Nevertheless, a significant amount of tracer remains bound to the tissue despite blocking. Possible reasons are non-specific binding due to the lipophilicity of the tracer and/or potential off-target effects.

However, in our first approach to utilize the tracer for in vivo PET studies, we found only low brain uptake after...
administering the compound via tail vein to a male rat (Fig. 6b, c). This can reflect the compounds limited BBB permeability, since a moderate brain-to-plasma ratio (0.44 vs. Donepezil = 6.3) had already been described for the parent, methoxy compound (Fig. 1a) after in vivo blood plasma-brain distribution studies [32]. On the other hand, this compound had been investigated in permeability measurements using Caco-2 cells, where it exhibited neither low passive permeability nor active efflux by membrane transport proteins like P-glycoprotein or breast cancer resistance protein [32].

Fig. 6. a Autoradiographic image of tissue binding assay with healthy mice brain slices incubated with [18F]-labeled BChE–tracer 4 without (left) and with (right) ethopropazine. Purple areas represent low binding; bright yellow areas represent high binding. b Dynamic PET images of sagittal sections after administration of radiotracer 4 in a healthy rat. Dark green areas represent high tracer accumulation; light green areas represent low accumulation. c Time-activity curves in each organ derived from the PET imaging.

Conclusion

In our study, we present design and evaluation of a novel 18F-PET radiotracer selectively targeting BChE with reversible mode of binding. Precursor and the respective cold compound are now synthetically easily accessible. Inhibitory potency of the cold compound was decreased compared to the parent compound. Therefore, future studies could additionally focus on 11C labeling at the methoxy group to completely retain inhibitory potency of the radiotracer. Radiolabeling was achieved in a reasonable time frame and a good radiochemical yield applying a standard procedure. Preliminary ex vivo autoradiography on mice brain slices preincubated with the tracer revealed its good binding to brain tissue and blocking studies with ethopropazine hydrochloride demonstrated its selectivity towards BChE. However, future studies should focus on determining possible reasons for the significant compound retention despite blocking with respect to potential off-target effects and non-specific binding. Our preliminary in vivo PET study showed only limited brain uptake of the tracer after tail vein injection. After the initial blood pool circulation, the tracer was accumulated in liver and kidneys and excreted fast into intestine and urine. The tracer’s ability to pass the BBB might be restricted. On the other hand, the parent compound, which served as design schedule for us, demonstrated neither low passive permeability nor active efflux. Due to these facts, the tracer will be applied in future studies towards its precise biodistribution to clarify the reason of its limited brain uptake.

Acknowledgments The authors are thankful to Dr. Jure Stojan (Medical faculty, University of Ljubljana, Slovenia) for helpful discussions regarding kinetic analysis and progress-curve analysis.

Funding Open Access funding enabled and organized by Projekt DEAL. This work was supported by the German Research Council (Deutsche Forschungsgemeinschaft DFG grants DE 1546/6-3 for M. Decker and HI 1789/3-3 Prof. T. Higuchi) and the Slovenian Research Agency (core financing P1-0208 and projects Z1-9195 granted to UK and NC-0009 to S. Gobec).

Compliance with Ethical Standards All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. Animal protocols were approved by the local Animal Care and Use Committee and conducted according to the Guide for the Care and Use of Laboratory Animals.

Conflict of Interest The authors declare that they have no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or
inhibitors with tunable duration of action by chemical modification of transferable carbamate units exhibit pronounced neuroprotective effect in an Alzheimer’s disease mouse model. J Med Chem 62:9116–9140

32. Košak U, Brus B, Knez D, Sink R, Žakelj S, Trontelj J, Pišlar A, Šlenc J, Gobec M, Živin M, Tratnjek L, Perše M, Salat K, Podkova A, Filipček B, Nachon F, Brazzolotto X, Więckowska A, Malawska B, Stojan J, Raščan IM, Kos J, Coquelle N, Colletier JP, Gobec S (2016) Development of an in-vivo active reversible butyrylcholinesterase inhibitor. Sci Rep 6:39495

33. McCluskey SP, Plisson C, Rabiner EA, Howes O (2020) Advances in CNS PET: the state-of-the-art for new imaging targets for pathophysiology and drug development. Eur J Nucl Med Mol Imaging 47:451–489

34. Sanchez-Crespo A (2013) Comparison of Gallium-68 and Fluorine-18 imaging characteristics in positron emission tomography. Appl Radiat Isot 76:55–62

35. Kesch C, Kratochwil C, Mier W, Kopka K, Giesel FL (2017) (68)Ga or (18)F for prostate cancer imaging? J Nucl Med 58:687–688

36. Ignatovich ZV, Gusak KN, Chernikhova TV, Kozlov NG, Koroleva EV (2007) Interaction of secondary amines with aromatic aldehydes-efficient method for synthesis of the functionalized heterocyclic amines. Chem Heterocycl Compd 43:1540–1543

37. Node M, Hori H, Fujita E (1976) Demethylation of aliphatic methyl ethers with a thiol and boron trifluoride. J. Chem. Soc. Perkin Trans. I:2237–2240

38. Košak U, Brus B, Gobec S (2014) Straightforward synthesis of orthogonally protected piperidin-3-ylmethanamine and piperidin-4-ylmethanamine derivatives. Tetrahedron Lett 55:2037–2039

39. Middleton WJ (1975) New fluorinating reagents. Dialkylaminosulfur fluorides. J Org Chem 40:574–578

40. Ellman GL, Courtney KD, Andres V, Featherstone RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7:88–95

41. Mesulam M, Geula C (1994) Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia. Ann Neurol 36:722–727

42. Meuling WJ, Jongen MJ, van Hemmen JJ (1992) An automated method for the determination of acetyl and pseudo cholinesterase in hemolyzed whole blood. Am J Ind Med 22:231–241

43. Jorissen WP, van der Beek PAA (1930) The oxidation of benzaldehyde. Recl Trav Chim Pays-Bas 49:138–141

44. Kabalka GW, Varma M, Varma RS, Srivastava PC, Knapp FF (1986) The tosylation of alcohols. J Org Chem 51:2386–2388

45. Mesulam MM, Guillorot A, Shaw P, Levey A, Duyse EG, Lockridge O (2002) Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine. Neuroscience 110:627–639

46. Reid GA, Chilukuri N, Darvesh S (2013) Butyrylcholinesterase and the cholinergic system. Neuroscience 234:53–68

47. Geula C, Nagykery N (2007) Butyrylcholinesterase activity in the rat forebrain and upper brainstem: postnatal development and adult distribution. Exp Neurol 204:640–657

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.